AMACR and prostate adenocarcinoma: Additionally, while PSA negativity is atypical for prostate adenocarcinoma, the absence of GATA3, a marker of urothelial origin, along with the positive AMACR, supported a diagnosis of prostatic ductal adenocarcinoma.